| __timestamp | Mesoblast Limited | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 5903000 |
| Thursday, January 1, 2015 | 23783000 | 2762000 |
| Friday, January 1, 2016 | 29763000 | 1114000 |
| Sunday, January 1, 2017 | 12065000 | 25573000 |
| Monday, January 1, 2018 | 5508000 | 6000000 |
| Tuesday, January 1, 2019 | 75173000 | 38845000 |
| Wednesday, January 1, 2020 | 81497000 | 50523000 |
| Friday, January 1, 2021 | 85731000 | 75463000 |
| Saturday, January 1, 2022 | 63572000 | 105767000 |
| Sunday, January 1, 2023 | 54922000 | 167512000 |
| Monday, January 1, 2024 | 41070000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Mesoblast Limited and Xenon Pharmaceuticals Inc. have shown distinct trends in their cost of revenue. Mesoblast's cost peaked in 2021, reaching approximately 86 million, before declining by 36% in 2024. In contrast, Xenon Pharmaceuticals saw a dramatic increase, with costs surging by over 180% from 2014 to 2023, peaking at around 168 million. This divergence highlights differing strategic approaches and market conditions. Notably, Xenon's data for 2024 is missing, indicating potential reporting delays or strategic shifts. These insights provide a window into the financial health and operational strategies of these biotech firms, offering valuable lessons for investors and industry analysts alike.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Cost of Revenue Comparison: Biogen Inc. vs Xenon Pharmaceuticals Inc.
Analyzing Cost of Revenue: Bio-Techne Corporation and Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
Walgreens Boots Alliance, Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Mesoblast Limited's Expenses
Cost of Revenue Comparison: Alkermes plc vs Mesoblast Limited
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited
Mesoblast Limited vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored